New Delhi, October 17

Dr Reddy’s Laboratories on Saturday said it along with Russian Direct Investment Fund (RDIF) has received approval from the Drug Control General of India (DCGI) to conduct Phase 2 and 3 human clinical trials for vaccine Sputnik V in India.

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials

, PM

Can’t be complacent, cautions PM

There is a decline in the daily cases and growth rate, but people must not get complacent. They must keep up efforts to contain the pandemic. Two pan-India studies on the genome of virus suggest there is no major mutation in virus.

 

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials

–>

“This will be a multi-centre and randomised controlled study, which will include safety and immunogenicity check,” the Hyderabad-based drug major said in a statement.

“This is a significant development that allows us to commence the clinical trial in India and we are committed to bringing in a safe and efficacious vaccine to combat the pandemic,” Dr Reddy’s Laboratories co-chairman and managing director GV Prasad said.

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trialsPrime Minister today reviewed the pandemic situation and preparations for vaccine delivery, distribution and administration.

Noting that there was a decline in the daily cases and the growth rate, he cautioned people against complacency and asked them to keep up efforts to contain the pandemic.

Active caseload falls below 8 lakh

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trialsThe country’s active caseload fell below eight lakh for the first time in one-and-a-half months and account for merely 10.7 per cent of the total cases, the Health Ministry said on Saturday. There are 7,95,087 active cases as on date. The active caseload was below the 8 lakh mark last on September 1. PTI

Vaccine distribution

In consultation with the states, an expert group is working on vaccine prioritisation and distribution.

Read original article here.